A neuroimunologia é o ramo da imunologia que estuda a relação entre sistema imune e o sistema nervoso. Muitos estudos têm demonstrado a capacidade direta de neurotransmissores em modular a resposta imune, assim como de citocinas em influenciar funções cognitivas. Neste contexto, o glutamato possui papel de destaque, por se tratar do neurotransmissor excitatório mais importante e mais abundante no sistema nervoso central dos mamíferos. Sua função é exercida através de dois tipos de receptores principais: i) os receptores ionotrópicos (iGluR) e ii) os receptores metabotrópicos (mGluR). A descoberta da expressão de receptores de glutamato em células do sistema imune tem despertado interesse científico, levantando questões acerca de sua expressão e função. No presente trabalho, avaliamos parâmetros como viabilidade celular, linfoproliferação e ativação de MAP quinase pelo receptor NMDAR esplenócitos totais e linfócitos cultivados in vitro. Nossos resultados demonstram que linfócitos em repouso e ativados apresentam diferentes perfis de expressão do receptor NMDAR. O uso do antagonista deste receptor, o MK801, foi capaz de reduzir a proliferação de linfócitos T CD4 e T CD8 estimulados com anti-CD3 em cultura de esplenócitos. Tal redução pode ser explicada por um aumento na taxa de morte celular, o que foi avaliado através de marcação com anexina-V, indicador de apoptose, ou 7-AAD, indicador de necrose. Para entendermos um pouco a respeito da sinalização do receptor NMDAR no sistema imune, avaliamos a fosforilação da MAP quinase ERK 1,2 em linfócitos T CD4 ativados na presença do agonista (NMDA) ou do antagonista (MK801) do receptor. Observamos um aumento na ativação desta quinase na presença de NMDA, o que é revertido na presença do MK801. Ao avaliar o papel do receptor NMDAR in vivo, verificamos uma redução significativa na gravidade da encefalomielite experimental auto-imune em animais tratados com MK801. Mais interessante, esta redução se correlaciona também com uma redução na fosforilação de ERK 1,2 em esplenócitos totais obtidos ao dia 7 pós-imunização. Em resumo, nossos dados sugerem que o receptor NMDA possui o papel de ativador de vias intracelulares importantes, como as da MAP quinase ERK 1,2; e que o seu bloqueio resulta em morte celular in vitro. Logo, isso indica a importância do glutamato como modulador da intensidade da resposta e viabilidade de linfócitos T CD4 e T CD8 in vitro e in vivo. Sendo assim, nossos resultados contribuem para um melhor entendimento dos fenômenos de imunoregulação, especialmente aqueles no campo da neuroimunologia ou neuroimunomodulação. / Neuroimmunology is a field within immunology which studies the relationship between the nervous system and the immune system. Several studies have demonstrated the direct ability of neurotransmitters in modulating the immune response, as for cytokines in influencing cognitive functions. In this context, glutamate stands out for being the most important and abundant neurotransmitter in the mammal central nervous system. Its role is exerted through two main types of receptor: i) ionotropic receptors (iGluR) and ii) metabotropic receptors (mGluR). The discovery of glutamate receptor expression in immune cells has led to scientific interest, raising issues concerning its expression and function. In the present study, we evaluated parameters such as cell viability, lymphoproliferation, and activation of the MAP quinase pathway by the NMDA receptor on total splenocytes and lymphocytes cultured in vitro. Our results demonstrate that naive and activated lymphocytes present different profiles of NMDA receptor expression. The use of MK801, an antagonist for this receptor, was able to reduce the T CD4 and T CD8 lymphocyte proliferation stimulated with anti-CD3 in splenocyte culture. Such reduction may be explained by the increase of the cellular death rate, evaluated by annexin-V staining, indicator of apoptosis or 7-AAD, indicator of necrosis. With the intent of understanding part of the NMDA receptor signaling in the immune system, we evaluated the ERK 1,2 MAP quinase phosphorylation in T CD4 lymphocytes activated in the presence of the agonist (NMDA) or the antagonist (MK801) of the receptor. We observed an increase in this quinase activation in the presence of NMDA, which is reversed by the MK801. When evaluating the role of the NMDA receptor in vivo, we verified a significant reduction in the degree of experimental auto-immune encephalomyelitis in animals treated with MK801. More interesting, this reduction also correlates to a reduction on the phosphorilation of ERK 1,2 in total splenocytes obtained at the seventh day post-immunization. In sum, our data suggest that the NMDA receptor has the role of activating important intracellular pathways, such as the MAP quinases ERK 1,2; and that its blockage results in cellular death in vitro. As so, this indicates the importance of glutamate as a modulator of the intensity of response and the viability of T CD4 e T CD8 lymphocytes in vitro e in vivo. Thus, our result contribute for a better understanding of the immunoregulation phenomena, especially those in the neuroimmunology ou neuroimmunomodulation field.

Le glutamate est le principal neurotransmetteur excitateur du système nerveux central. Il est responsable de la majorité des transmissions synaptiques. En revanche, cet acide aminé naturel est aussi impliqué dans de nombreuses neuropathologies notamment en cas de surconcentration au niveau des synapses. Les récepteurs métabotropiques du glutamate, capables de moduler la transmission synaptique, constituent des cibles thérapeutiques prometteuses. Ces récepteurs sont divisés en trois groupes et notre laboratoire s’est focalisé sur ceux du groupe III et particulièrement le sous-type 4 qui présente des caractéristiques intéressantes dans le traitement symptomatique de la douleur et de la maladie de Parkinson. Le manque d’outils pharmacologiques de ce récepteur nous a poussé à synthétiser de nouveaux agonistes orthostériques à partir du composé référence, le LSP4-2022. Cette molécule est issue de nombreuses optimisations chimiques du (S)-PCEP provenant lui d’un screening virtuel. Durant ces trois années de doctorat, nous avons pu peaufiner la relation structure-activité autour du LSP4-2022 en synthétisant des nouveaux analogues fluorés et hétérocycliques. En parallèle, une seconde étude nous a permis d’attribuer la configuration des deux diastéréomères constituants tous les composés testés à ce jour / Glutamate is the major excitatory neurotransmitter in the central nervous system. It is responsible of the majority of synaptic transmissions. In contrast, this natural amino acid is also involved in numerous neuropathologies and particularly in case of glutamate overconcentration in the synapse. Metabotropic glutamate receptors, that can modulate synaptic transmission, thus constitute promising therapeutic targets. These receptors are divided in three groups and our laboratory has been focused in group III and especially subtypes 4 which own interested properties in symptomatic treatment of pain and Parkinson Disease. The lack of pharmacological tools targeting this receptor prompts us to synthesize novel orthosteric agonist from the hit compound LSP4-2022. This molecule was obtained after several chemical optimizations from (S)-PCEP discovered from virtual screening. During my Ph.D., we could refine the structure-activity relationship of LSP4-2022 synthesizing new fluorinated and heterocyclic derivatives. Besides, a second study was carried out to identify the configuration of the two diastereomers which form tested compounds

A ativação excessiva dos receptores NMDA tem sido descrita no disparo da morte neuronal que ocorre em doenças, como o glaucoma. É possível que a combinação de subunidades (NR2A-D) possa ativar vias de sinalização intracelulares que resultam na morte ou sobrevivência. Nosso objetivo foi investigar o envolvimento de subunidades NR2 e Rac1, membro da família Rho GTPase, na morte de neurônios da retina. A morte induzida por glutamato in vitro foi reduzida após a inibição de Rac1 e bloqueio de NR2B, mas não das subunidades NR2C/D. Resultados semelhantes foram obtidos in vivo após injeção intravítrea NMDA, e a detecção de Rac1 ativo, principalmente, nos processos de glia de Müller foi inibida pelo bloqueio NR2B. Além disso, a produção de TNF-<font face=\"Symbol\">&#945; após a injeção de NMDA foi reduzida pelo bloqueio de NR2B e Rac1. Assim, nossos resultados sugerem que a excitotoxicidade via receptores NR2B/NMDA ativa Rac1 em células da glia de Müller, que por sua vez controla a produção de TNF-<font face=\"Symbol\">&#945 possível responsável pela morte de células ganglionares da retina. / Overactivation of NMDA receptors has been described to trigger neuronal death that occurs in diseases such as glaucoma. It is possible that the combination of subunits (NR2A-D) activate intracellular signaling pathways that result in death or survival. Our aim was to investigate the involvement of NR2 subunits and Rac1, a member of Rho GTPase family, in retinal neuronal death. Glutamate-induced neuronal death in vitro was reduced after Rac1 inhibition and by NR2B blocking, but not NR2C/D subunits. Similar results were obtained in vivo after NMDA intravitreous injection, although active Rac1 was mainly detected in Müller glia processes, and it was inhibited by NR2B blockade. In addition, TNF-<font face=\"Symbol\">&#945 level after NMDA injection were reduced by NR2B blocking and Rac1. Thus, our results suggest that excitotoxicity via NR2B/NMDA receptors activate Rac1 in Müller glia cells, which in turn controls the TNF-<font face=\"Symbol\">&#945 production that triggers retinal ganglion cell death.

1. The effects of external H-7, a potent protein kinase inhibitor, on the responses mediated by γ-aminobutyric acid A type (GAGA(A))-, nicotinic acetylcholine (nicotinic ACh)-, ionotropic 5-hydroxytryptamine (5-HT3)-, adenosine 5'-triphosphate (ATP)-, N-methyl-D-aspartate (NMDA)- and kainate (KA)-receptors were studied in freshly dissociated rat dorsal root ganglion neurone by use of whole cell patch-clamp technique. 2. External H-7 (1-1000 μM) produced a reversible, dose-dependent inhibition of whole cell currents activated by GABA, ACh and 5-HT. 3. Whole-cell currents evoked by ATP, 2-methylthio-ATP, NMDA and KA were sensitive to external H-7. 4. External H-7 shifted the dose-response curve of GABA-activated currents downward without changing the EC50 significantly (from 15.0 ± 4.0 μM to 18.0 ± 5.0 μM). The maximum response to GABA was depressed by 34.0 ± 5.3%. This inhibitory action of H-7 was voltage-independent. 5. Intracellular application of H-7 (20 μM), cyclic AMP (1 mM) and BAPTA (10 mM) could not reverse the H-7 inhibition of GABA-activated currents. 6. The results suggest that external H-7 selectively and allosterically modulates the functions of GABA(A)-, nicotine ACh- and 5-HT3 receptors via a common conserved site in the external domain of these receptors.

Indiana University-Purdue University Indianapolis (IUPUI) / Brain responds to an array of diverse challenges that are defined as either exteroceptive stress, involving cognitive processing of sensory information from the external environment and or interoceptive stress, detected through sensory neural or chemical cues from the internal environment. The physiological response to most stresses consists of autonomic responses that are essential for animal survival in the face of a threatening circumstance. However, it is known that exposition to continuous situations of stress is involved in the development of a series of diseases such as hypertension, myocardial infarction and panic syndrome. Several studies have shown that cells in a specific area of the brain, the dorsomedial hypothalamus (DMH), are involved in the response produced during emotional stress. However, the role of glutamatergic transmission in the DMH in the increase in body temperature induced by experimental stress has not been examined. Research findings thus far indicate that neurons in the DMH play a role in thermoregulation and that local glutamate receptors may be involved. The hypothesis of this thesis is that activity at ionotropic glutamate receptors in the DMH is necessary for the thermogenic response induced by experimental stress. In the present work, microinjections of kynurenate, an excitatory amino acid antagonist, NBQX (2, 3-dihydroxy-6-nitro-7-sulfamoyl-benzo[f]quinoxaline-2,3-dione), an AMPA/kainate receptor antagonist, DL-2-amino-5-phosphonovaleric acid (APV), an NMDA receptor antagonist, and a mixture of NBQX and APV, were delivered to the DMH before exposure to experimental stress. The stress paradigms used include models for exteroceptive stress and interoceptive stress. The results show that inhibition of both NMDA and non-NMDA receptors is necessary to abolish the thermogenic response produced by all stress paradigms tested. Furthermore, there appears to be a difference in the degree of attenuation of the thermogenic response produced by either inhibition of NMDA receptors or non-NMDA receptors. Together these results support a definite role for ionotropic glutamate receptors within DMH region in the thermogenic response to stress. These results also finally show that the DMH is involved in all the major physiological stress responses including increase in plasma ACTH, increase in heart rate, blood pressure and now temperature as well.

No description available.

La maladie de Parkinson (MP) est une maladie neurodégénérative chronique qui apparait en moyenne à partir 55 ans. Sa cause reste inconnue mais son apparition et son développement sont corrélés avec la perte progressive des neurones dopaminergique de la substance noire qui innervent les ganglions de la base (GB). Jusqu'à ce jour le traitement le plus efficace est basé sur la compensation du déficit en dopamine (DA) par l'administration de son précurseur, la L-DOPA, qui est métabolisé en DA. Ce traitement améliore les symptômes moteurs de la maladie et donc la qualité de vie des patients. Néanmoins, après une certaine période des effets secondaires invalidants apparaissent, en particulier des fluctuations motrices et des mouvements anormaux involontaires appelés dyskinésies. De plus, ce traitement n'apporte pas de réponse à la progression de la dégénérescence et donc de la maladie. C'est pour ces raisons que la communauté scientifique est à la recherche d'une thérapie pharmacologique alternative à la L-DOPA, ou du moins visant à minimiser ses effets indésirables. Dans ce contexte, les récepteurs métabotropiques du glutamate, en particulier mGluR4, semblent constituer une cible privilégiée. En effet, mGluR4 est situé à des synapses des GB supposées hyperactives dans la MP, et son activation par des moyens pharmacologiques pourrait donc rétablir une activité normale grâce à son action inhibitrice sur la libération de neurotransmetteur. Nos résultats démontrent le bien-fondé de cette hypothèse sur le plan fonctionnel, en utilisant un nouvel agoniste allostérique spécifique de mGluR4, Lu AF21934. / Parkinson's disease (PD) is a progressive neurodegenerative disorder that appears around 55 years of age. The causes of PD remain unknown but its appearance and progression are correlated with the progressive loss of dopaminergic neurons of substantia nigra pars compacta innervating the basal ganglia (BG). Up to date, the most efficient treatment is based on restoring a normal level of dopamine (DA) in the brain by the administration of L-DOPA, a DA precursor that is metabolized to DA. However, at long term, L-DOPA treatment induces some side-effects, in particular the highly disabling L-DOPA-induced dyskinesia (LID). For this reason, the scientific community is searching for a pharmacological treatment alternative to L-DOPA and/or minimizing LID. In this context, metabotropic glutamate receptors, in particular mGluR4, are targets of interest. mGlu4 are localized at presynaptic terminals within BG circuitry that become hyperactive in PD. For this reason, mGluR4 has been considered a key strategic target for non-dopaminergic pharmacological treatments aimed at modulating these synapses, due to its ability to reduce neurotransmitter release. Herein we provide physiological and functional support to this hypothesis using Lu AF21934, a novel selective and brain-penetrant mGluR4 positive allosteric modulator (PAM). By in vitro electrophysiological recordings we demonstrate that Lu AF21934 inhibits corticostriatal synaptic transmission. In rats rendered parkinsonian, Lu AF21934 combined with sub-threshold doses of L-DOPA acted synergistically in alleviating akinesia in a dose-dependent manner and, notably, also reduced the incidence of LID.

The induction of synaptic plasticity at CA1 synapses requires NMDAR activation. Modulation of NMDAR function by various GPCRs can shift the thresholds for LTP and LTD induction and contribute to metaplasticity. Here we showed that the activity of GluN2A- and GluN2B-containing NMDARs is differentially regulated by Gαi/o-coupled, Gαq- and Gαs-coupled receptors. Furthermore, enhancing the relative function of GluN2A-to-GluNB NMDAR activity by GPCRs can alter the balance of LTP and LTD induction and contribute to metaplasticity. In CA1 neurons, activation of the Gαs-coupled D1/D5R selectively recruited Fyn kinase and enhanced GluN2B-mediated NMDAR currents. Biochemical experiments confirmed that D1/D5R stimulation activates Fyn kinase and enhances the tyrosine phosphorylation of GluN2B subunits. In contrast, activation of the Gαq-coupled PAC1R selectively recruited Src kinase to enhance the function of GluN2A-containing NMDARs. Enhancing the functional ratio of GluN2A-to-GluN2B subunits by PAC1R activation lowered the threshold for LTP induction whereas enhancing the functional ratio of GluN2B-to-GluN2A subunits by D1/D5R activation increased the threshold for LTP induction. Unexpectedly, activation of the Gαi/o-coupled mGluR2/3 enhanced NMDAR-mediated function via a previously unidentified mechanism. Inhibition of the cAMP-PKA pathway via mGluR2/3 activation resulted in activation of Src via decreased phosphorylation of its C-terminal Tyr527 by Csk. Stimulation of mGluR2/3 selectively potentiated the function of GluN2A-containing NMDARs but whether it shifted the modification threshold θm to the left requires further investigation.

Η παρούσα διατριβή ασχολήθηκε με τη μελέτη της έκφρασης των υπομονάδων των υποδοχέων του γλουταμινικού οξέος και του γ-αμινοβουτυρικού οξέος (GABA) στα βασικά γάγγλια και τον φλοιό των εγκεφαλικών ημισφαιρίων του μυός weaver. Παράλληλα, μελετήθηκε η έκφραση των νευροπεπτιδίων εγκεφαλίνης και δυνορφίνης στα βασικά γάγγλια του μυός weaver. O μυς weaver χαρακτηρίζεται από προοδευτική, γενετικά επαγόμενη εκφύλιση των ντοπαμινεργικών κυττάρων του μεσεγκεφάλου, κυρίως αυτών οι οποίοι καταλήγουν στο ραβδωτό σώμα. Για αυτόν τον λόγο, θεωρείται ένα καλό μοντέλο της νόσου Parkinson και η μελέτη των νευροχημικών μεταβολών που συμβαίνουν στον εγκέφαλο του παραπάνω μυός, αποτελεί πολύτιμο εργαλείο για τη διερεύνηση των παθογενετικών μηχανισμών της νόσου. Mε την τεχνική του υβριδισμού in situ, προσδιορίστηκαν τα επίπεδα mRNA των υπομονάδων z1, ε1 και ε2 του υποδοχέα NMDA, των υπομονάδων KA2 και GluR6 του υποδοχέα καϊνικού οξέος, των υπομονάδων α1, α2, α4, β2 και β3 του υποδοχέα GABAA, καθώς και των πρόδρομων πολυπεπτιδίων προ-προεγκεφαλίνη και προδυνορφίνη. Η μελέτη πραγματοποιήθηκε σε φυσιολογικούς μύες (+/+) και μύες weaver (wv/wv), στις ηλικίες των 26 ημερών, 3 μηνών και 6 μηνών μετά τη γέννηση. Όσον αφορά στους υποδοχείς του γλουταμινικού οξέος, τα αποτελέσματά μας υπέδειξαν αύξηση στην έκφραση των υπομονάδων z1, ε2, ΚΑ2 και GluR6 στο ραβδωτό σώμα των μυών weaver, σε σχέση με τους φυσιολογικούς. Η αύξηση στο mRNA των υπομονάδων z1, ε2 και GluR6 παρατηρήθηκε μόνο στην ηλικία των 6 μηνών, ενώ το mRNA της υπομονάδας KA2, παρουσίασε αύξηση και στις τρεις ηλικίες που μελετήθηκαν. Οι αυξήσεις της έκφρασης των υπομονάδων z1, ε2, ΚΑ2 και GluR6 συμφωνούν και πιθανόν εξηγούν τις αυξήσεις στα επίπεδα των θέσεων δέσμευσης για τους υποδοχείς NMDA και μη-NMDA, οι οποίες έχουν βρεθεί από παλαιότερες μελέτες του εργαστηρίου μας στο ραβδωτό σώμα των μυών weaver ηλικίας 6 μηνών. Με βάση βιβλιογραφικά δεδομένα, υποστηρίζουμε ότι η καθυστερημένη αύξηση στην έκφραση των υπομονάδων z1, ε2 και GluR6 κατά πάσα πιθανότητα συντελείται μέσω επαγωγής του μεταγραφικού παράγοντα ΔfosB, σε απόκριση προς τη μείωση της ντοπαμίνης. Στον σωματοαισθητικό φλοιό των μυών weaver ηλικίας 26 ημερών, παρατηρήθηκε αύξηση στην έκφραση των υπομονάδων z1, ε1, ε2 και KA2, η οποία θα μπορούσε να οφείλεται στη μειωμένη θαλαμοφλοιϊκή γλουταμινεργική είσοδο. Όσον αφορά στους υποδοχείς GABAA, παρατηρήθηκε αύξηση στα επίπεδα mRNA των υπομονάδων α4 και β3, στο ραβδωτό σώμα των μυών weaver ηλικίας 6 μηνών, η οποία συμφωνεί και μπορεί να εξηγήσει την αύξηση στα επίπεδα των θέσεων δέσμευσης για τους υποδοχείς GABAA, η οποία έχει βρεθεί σε προηγούμενη μελέτη του εργαστηρίου μας, στο ραβδωτό σώμα των μυών weaver ηλικίας 6 μηνών. Σκοπεύουμε να ελέγξουμε την πιθανότητα, η αύξηση της έκφρασης της υπομονάδας α4, να υποδεικνύει μία αύξηση του αριθμού των εξωσυναπτικών υποδοχέων GABAA στους νευρώνες προβολής του ραβδωτού σώματος. Στην ωχρά σφαίρα των μυών weaver ηλικίας 6 μηνών, παρατηρήθηκε μείωση των επιπέδων mRNA των υπομονάδων α1 και β2, υποδεικνύοντας μία μείωση του αριθμού των υποδοχέων GABAA, η οποία ήταν αναμενόμενη, λόγω της αυξημένης GABAεργικής εισόδου στην εν λόγω εγκεφαλική περιοχή του μυός weaver. Στον σωματοαισθητικό φλοιό, παρατηρήθηκε μείωση στην έκφραση των υπομονάδων α2 και β2 και ταυτόχρονα αύξηση στην έκφραση των υπομονάδων α4 και β3. Με βάση βιβλιογραφικά δεδομένα, προτείνουμε ότι οι μεταβολές αυτές μπορεί να αντανακλούν μείωση στον αριθμό των συναπτικών και αύξηση στον αριθμό των εξωσυναπτικών υποδοχέων GABAA, σε απόκριση προς τη μειωμένη GABAεργική είσοδο προς τους νευρώνες του σωματοαισθητικού φλοιού του μυός weaver. Όσον αφορά στην έκφραση των πολυπεπτιδίων, το mRNA της προ-προεγκεφαλίνης, παρουσίασε αύξηση στο ραβδωτό σώμα των μυών weaver, μόνο στην ηλικία των 6 μηνών, ενώ το mRNA της προδυνορφίνης, παρουσίασε μείωση στην παραπάνω περιοχή, στην ηλικία των 26 ημερών και αύξηση στις μεγαλύτερες ηλικίες. Σύμφωνα με τα βιβλιογραφικά δεδομένα υποστηρίζουμε ότι: α) η καθυστερημένη αύξηση της έκφρασης της προ-προεγκεφαλίνης στο ραβδωτό σώμα του μυός weaver, οφείλεται στη μείωση της τονικής ανασταλτικής ρυθμιστικής δράσης της ντοπαμίνης στην έκφραση του εν λόγω γονιδίου και πιθανώς συντελείται μέσω του μεταγραφικού παράγοντα ΔfosB, β) ο παραπάνω μεταγραφικός παράγοντας είναι κατά πάσα πιθανότητα υπεύθυνος και για την καθυστερημένη επαγωγή της έκφρασης της προδυνορφίνης στο ραβδωτό σώμα των μυών weaver και γ) η μείωση του παραπάνω mRNA στην ηλικία των 26 ημερών οφείλεται στη μείωση της τονικής διεγερτικής δράσης της ντοπαμίνης στην έκφραση του εν λόγω γονιδίου. Τέλος, το γεγονός ότι οι μεταβολές των mRNA των διαφόρων υπομονάδων και νευροπεπτιδίων δεν ήταν οι ίδιες στις διάφορες ηλικίες που μελετήθηκαν υποδεικνύει ότι κατά την πρόοδο της ντοπαμινεργικής εκφύλισης των ντοπαμινεργικών νευρώνων του μεσεγκεφάλου διαφορετικοί μηχανισμοί ευθύνονται για την πρόκληση των αλλαγών στην έκφραση των υπό μελέτη γονιδίων. / In the present study we investigated the expression of the subunits of glutamate and γ-aminobutyric acid (GABA) receptors in basal ganglia and cerebral cortex of the weaver mouse. We also studied the expression of striatal neuropeptides, which are important neuromodulators of the synaptic transmission in the basal ganglia circuitry. The weaver mouse is characterized by a progressive, genetically induced degeneration of the mesencephalic dopaminergic neurons, especially those that project to the striatum. For this reason, the weaver mouse is a useful model for clarifying the pathogenetic mechanisms that underly Parkinson’s disease. Using the in situ hybridization method, the mRNA levels of the ΝΜDA subunits z1, ε1 and ε2, the kainate subunits KΑ2 and GluR6, the GABAA subunits α1, α2, α4, β2 and β3, as well as the mRNA levels of the precursor polypeptides pre-proenkephalin and prodynorphin, were estimated. The study was performed using wild-type (+/+) and weaver mice (wv/wv) of the following ages: 26 days, 3 months and 6 months. Concerning the glutamate receptors, an increase in the mRNA levels of z1, ε2, KA2 and GluR6 subunits was indicated in the weaver striatum, compared to the wild type. The z1, ε2 and GluR6 mRNA increases were observed only at the age of 6 months, whereas the KA2 mRNA increase was observed at all three ages studied. The increases in z1, ε2, ΚΑ2 and GluR6 mRNA expression are in agreement and probably explain the increased levels of ΝΜDA- and non-NMDA-sensitive binding sites that we had previously found in the 6 months old weaver striatum. Based on bibliographic data, we suggest that the delayed increases in z1, ε2 and GluR6 mRNA levels, are probably mediated by the delayed induction of the ΔfosB transcription factor, in response to the reduction of striatal dopamine levels. In the somatosensory cortex of 26 day old weaver mice, an increase in the levels of z1, ε1, ε2 and ΚΑ2 mRNAs was observed. The above increases can be attributed to the decreased thalamocortical glutamatergic imput. Concerning the GABAA receptors, the observed increases of the α4 and β3 mRNA levels in the 6 months old weaver striatum are in agreement and probably explain the increased levels of GABAA binding sites that we had previously found in the 6 months old weaver striatum. We are going to test the hypothesis, that the α4 mRNA increase might indicate an increase in the number of extrasynaptic GABAA receptors in striatal projection neurons. In the 6 months old weaver globus pallidus, the observed decrease in α1 and β2 mRNA levels was expected, since the GABAergic transmission is increased in the above region of the weaver brain. In the weaver somatosensory cortex, a decrease in the α2 and β2 mRNA levels and an increase in the α4 and β3 mRNA levels were observed. Based on bibliographic data, we suggest that the above alterations probably indicate a differential regulation of the synaptic versus extrasynaptic cortical GABAA receptors, in response to the decreased GABAergic presynaptic input to the weaver cortical neurons. Concerning the expression of the striatal neuropeptides, the pre-proenkephalin mRNA was increased in the weaver striatum, only at the age of 6 months. In contrast, prodynorphin mRNA was decreased in the 26 day old weaver striatum, whereas it was increased in the 3 and 6 months old weaver striatum. Based on bibliographic data, we suggest that: a) the delayed increase in the expression of pre-proenkephalin could be caused by the reduction of the tonic dopaminergic inhibitory control on the expression of the above gene in the dopamine-depleted weaver striatum and is probably mediated by the ΔfosB transcription factor; b) the above transcription factor could be responsible for the delayed induction of the prodynorphin expression in the weaver striatum as well, and c) the decrease of prodynorphin mRNA in the 26 day old weaver striatum could be attributed to the reduction of the dopaminergic stimulatory control on the expression of the above gene. Finally, the different pattern of expression alterations among the three ages studied indicates that distinct mechanisms are responsible for the observed changes, during the progress of the dopaminergic degeneration of the weaver brain.

The Group III metabotropic glutamate receptors (mGluR) are located presynaptically on axon terminals and act as autoreceptors and heteroreceptors by inhibiting neurotransmitter release. Much has been learned about these receptors through exogenous application of L-serine-O-phosphate (L-SOP), an endogenous amino acid derivative and known activator of the Group III mGluRs. We hypothesized that L-SOP is the endogenous co-agonist at the high affinity Group III mGluR, mGluR4. We found the EC50 of L-SOP at mGluR4 was 0.5 μM, and determined that the concentration of L-SOP in whole brain was approximately 5 μM. An immunocytochemical survey revealed that cells containing the enzymatic machinery necessary for L-SOP synthesis and metabolism were observed in two brain regions known to express mGluR4, namely, cerebellum and hippocampus. In the cerebellum, the L-SOP synthetic and metabolic enzymes were found in Bergmann glia and Purkinje cells, two cells which form a tripartite synapse with parallel fiber axon terminals where the mGluR4 subtype is exclusively expressed at high levels. In the hippocampus, the L-SOP metabolic enzyme was detected in young neurons emanating from the neurogenic subventricular zone. Attempts to raise endogenous levels of L-SOP by crippling the L-SOP metabolizing enzyme (phosphoserine phosphatase), over-expressing the L-SOP synthesizing enzyme (phosphoserine aminotransferase), or through dietary protein restriction, to study the effects on neurotransmission and neurodevelopment in the central nervous system (CNS) were unsuccessful, suggesting that the production of L-SOP remains stable despite manipulation of the synthetic and metabolic enzymes. Finally, the ability of L-SOP to modulate glutamate release from presynaptic terminals was examined in cerebellar synaptosomes. Co-incident activation of presynaptic mGluR4 and presynaptic GABAA receptors facilitated glutamate release, suggesting that simultaneous activation of parallel fibers and Bergmann glia may serve to enhance synaptic transmission. This observation expands the traditional view of Group III mGluRs acting solely as inhibitory autoreceptors. Taken together, these results provide compelling evidence to support the hypothesis that L-SOP is the endogenous agonist at mGluR4, and possibly other Group III mGluRs.